APAC Breast Cancer Therapeutics Market revenue to hit $7.5 Bn by 2028

Published Date: 2022-03-10

Request a sample

APAC Breast Cancer Therapeutics Market size is set to cross USD 7.5 billion by 2028, according to a latest forecast report by Graphical Research.

The advancements in cancer biology and pharmacology promoting drug development are set to propel the market growth. The focused researcher’s study and the advent of innovative technologies are driving the development of novel therapies for breast cancer treatment.  Ongoing studies in the countries across the Asia Pacific region are focusing to address disparities and enhance the quality of life for survivors of the disease. In recent years, scientists are enabled to study new medications along with novel combinations of existing treatments owing to advancements in cancer biology and pharmacology. There is a new emphasis on adding targeted therapies to hormone therapy for advanced or metastatic HR-positive breast cancer. Moreover, computer-aided drug discovery (CADD) has developed as a powerful and promising technology for rapid, cost-effective, and more precise drug design. Recently, the rapid growth of computational pharmacology for anticancer therapies has exhibited a positive impact on breast cancer drug design and has also delivered significant insights into the area of breast cancer therapy.

The breast cancer care in the Asia Pacific region has improved significantly over the past few years, owing to the launch of several screening and diagnostic programs in the countries across the region. In Asia Pacific countries comprising China and Japan, breast cancer has long been one of the leading causes of cancer death. As precise breast cancer treatment is of primary importance, various government and non-government bodies in the region are coming forth with different screening and diagnostic programs. For instance, in 2019, the China Anti-Cancer Association prepared an interdisciplinary expert group to develop & implement three large-scale breast cancer screening programs for urban and rural women in the country. The guidelines for mammographic screening were developed for women aged 40–74 years and with clinical breast examination for women aged 40–64 years in Japan. As a result, the countries in the region are emphasizing on establishing novel strategies to enhance access to high quality screening and diagnostic programs that identify, prevent, and treat complications associated with breast cancer. Further, numerous campaigns are running to promote and spread positive messages pertaining to the significance of early-stage breast cancer diagnosis.

The chemotherapy segment will reach USD 555 million revenue by 2028 owing to the rising demand for advanced chemotherapy after breast cancer surgery to destroy any undetected cancer cells and lessen the risk of cancer recurring or spreading to other parts of the patient’s body. These therapies deliver multiple benefits in shrinking the tumor cells and reducing the growth of cancerous cells, thereby augmenting the life span of a patient that will result in surging demand for breast cancer therapeutics in the coming years. Many oncologists recommend chemotherapy medications after an early-stage breast cancer surgery to avoid further multiplication of cancerous cells that will propel the segmental revenue positively. Some of the chemotherapy medicines comprising Taxotere, Abraxane, Cytoxan, and Adriamycin among others are widely used to help with breast cancer symptoms and increase patient’s life expectancy.

Browse detailed statistical insights from the report, “Asia Pacific Breast Cancer Therapeutics Market Forecast 2028 By Therapy (Targeted Therapy, Hormonal Therapy, Chemotherapy, Immunotherapy), Research Report, Country Outlook (U.S., Canada), COVID-19 Impact Statistics, Price Trends, Historic Data, Growth Prospects, Competitive Industry Share” along with the table of contents (ToC) @


Surging breast cancer cases are also contributing to the adoption of chemotherapy drugs in breast cancer treatment procedures. As per the World Health Organization (WHO), one of the most common cancers is breast cancer that can be cured if detected early and treated effectively. Further, the WHO is providing technical assistance through the WHO Global Breast Cancer Initiative to support the government of several nations to improve breast cancer control and reduce avoidable deaths from breast cancer. Thus, several advantages delivered by chemotherapy along with these favourable initiatives are expected to drive market growth.

China breast cancer therapeutics industry will exceed USD 1.9 billion by 2028 due to the surging prevalence of breast cancer, rising healthcare expenditure, and increasing demand for advanced cancer care among others. As per the American Society of Clinical Oncology Journal, in 2018, breast cancer incidence was 36.1 per 100,000 and breast cancer mortality was 8.8 per 100,000 for China. Thus, as the number of breast cancer cases increases, a huge demand for breast cancer therapeutics is expected to witness that in turn is expected to fuel the industry growth. The entry of new biotech companies, a focused R&D portfolio, leadership in cell therapy, and emphasis on immuno-oncology are driving the quality of cancer research in China. The Chinese government has also implanted several initiatives comprising the healthcare reform to introduce a basic universal healthcare system that can provide safe, effective, and affordable healthcare services to cancer patients in China. These favorable initiatives are implemented by both government and non-government organizations that are further projected to increase the market revenue.

APAC breast cancer therapeutics market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD million from 2017 to 2028, for the following segments:

Asia Pacific Market, By Therapy

  • Targeted Therapy
  • Hormonal Therapy
  • Chemotherapy
  • Immunotherapy

The above information has been provided for the following countries:

  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Philippines
    • New Zealand